Perry Elliott1, Philippe Charron2, Juan Ramon Gimeno Blanes3, Luigi Tavazzi4, Michal Tendera5, Marème Konté6, Cécile Laroche6, Aldo P Maggioni6. 1. Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK perry.elliott@ucl.ac.uk. 2. Centre de Référence des Maladies Cardiaques Héréditaires, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France. 3. Cardiac Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. 4. GVM Care and Research, E.S. Health Science Foundation, Maria Cecilia Hospital, Cotignola, Italy. 5. 3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland. 6. EURObservational Research Programme, European Society of Cardiology, Sophia-Antipolis, France.
Abstract
AIMS: Cardiomyopathies are a heterogeneous group of disorders associated with premature death due to ventricular arrhythmia or heart failure. The purpose of this study was to examine the characteristics of patients enrolled in the pilot phase of the EURObservational Research Programme (EORP) cardiomyopathy registry. METHODS AND RESULTS: Between 1 December 2012 and 30 November 2013, four cardiomyopathy phenotypes were studied: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM). Twenty-seven centres in 12 countries participated; 1115 patients were enrolled. The commonest cardiomyopathy was HCM (n = 681), followed by DCM (n = 346), ARVC (n = 59), and RCM (n = 29); 423 patients (46.4% of those reported) had familial disease; and 56 (5.0%) had rare disease phenocopies. Median age at enrolment and diagnosis was 54 [interquartile range (IQR), 42-64] and 46 years (IQR, 32-58), respectively; fewer patients with ARVC and more with RCM were diagnosed in the upper age quartile (P < 0.0001). There was a male predominance for all cardiomyopathies except RCM (P = 0.0023). Most patients were in New York Heart Association functional class I (n = 813) at enrolment; 139 (12.5%) reported syncope, most frequently in ARVC (P = 0.0009). Five hundred and seven (45.5%) patients underwent cardiac magnetic resonance imaging, 117 (10.6%) endomyocardial biopsy, and 462 (41.4%) genetic testing with a causative mutation reported in 236 individuals (51.1%). 1026 patients (92.0%) were receiving drug therapy; 316 (28.3%) had received an implantable cardioverter defibrillator (highest proportion in ARVC, P < 0.0001). CONCLUSION: This pilot study shows that services for patients with cardiomyopathy are complex, requiring access to a large range of invasive and non-invasive investigations and involvement of multidisciplinary teams. Treatment regimens are equally multifaceted and show that patients are likely to need long-term follow-up in close liaison with expert centres. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Cardiomyopathies are a heterogeneous group of disorders associated with premature death due to ventricular arrhythmia or heart failure. The purpose of this study was to examine the characteristics of patients enrolled in the pilot phase of the EURObservational Research Programme (EORP) cardiomyopathy registry. METHODS AND RESULTS: Between 1 December 2012 and 30 November 2013, four cardiomyopathy phenotypes were studied: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM). Twenty-seven centres in 12 countries participated; 1115 patients were enrolled. The commonest cardiomyopathy was HCM (n = 681), followed by DCM (n = 346), ARVC (n = 59), and RCM (n = 29); 423 patients (46.4% of those reported) had familial disease; and 56 (5.0%) had rare disease phenocopies. Median age at enrolment and diagnosis was 54 [interquartile range (IQR), 42-64] and 46 years (IQR, 32-58), respectively; fewer patients with ARVC and more with RCM were diagnosed in the upper age quartile (P < 0.0001). There was a male predominance for all cardiomyopathies except RCM (P = 0.0023). Most patients were in New York Heart Association functional class I (n = 813) at enrolment; 139 (12.5%) reported syncope, most frequently in ARVC (P = 0.0009). Five hundred and seven (45.5%) patients underwent cardiac magnetic resonance imaging, 117 (10.6%) endomyocardial biopsy, and 462 (41.4%) genetic testing with a causative mutation reported in 236 individuals (51.1%). 1026 patients (92.0%) were receiving drug therapy; 316 (28.3%) had received an implantable cardioverter defibrillator (highest proportion in ARVC, P < 0.0001). CONCLUSION: This pilot study shows that services for patients with cardiomyopathy are complex, requiring access to a large range of invasive and non-invasive investigations and involvement of multidisciplinary teams. Treatment regimens are equally multifaceted and show that patients are likely to need long-term follow-up in close liaison with expert centres. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Juan R Gimeno; Perry M Elliott; Luigi Tavazzi; Michal Tendera; Juan P Kaski; Cecile Laroche; Roberto Barriales-Villa; Petar Seferovic; Elena Biagini; Eloisa Arbustini; Luis R Lopes; Ales Linhart; Jens Mogensen; Albert Hagege; Maria A Espinosa; Aly Saad; Aldo P Maggioni; Alida L P Caforio; Philippe H Charron Journal: Eur Heart J Qual Care Clin Outcomes Date: 2021-03-15
Authors: Chen-Ching Yuan; Katarzyna Kazmierczak; Jingsheng Liang; Zhiqun Zhou; Sunil Yadav; Aldrin V Gomes; Thomas C Irving; Danuta Szczesna-Cordary Journal: Proc Natl Acad Sci U S A Date: 2018-02-20 Impact factor: 11.205
Authors: Chen-Ching Yuan; Katarzyna Kazmierczak; Jingsheng Liang; Rosemeire Kanashiro-Takeuchi; Thomas C Irving; Aldrin V Gomes; Yihua Wang; Thomas P Burghardt; Danuta Szczesna-Cordary Journal: Cardiovasc Res Date: 2017-08-01 Impact factor: 10.787
Authors: Carolyn Y Ho; Sharlene M Day; Euan A Ashley; Michelle Michels; Alexandre C Pereira; Daniel Jacoby; Allison L Cirino; Jonathan C Fox; Neal K Lakdawala; James S Ware; Colleen A Caleshu; Adam S Helms; Steven D Colan; Francesca Girolami; Franco Cecchi; Christine E Seidman; Gautam Sajeev; James Signorovitch; Eric M Green; Iacopo Olivotto Journal: Circulation Date: 2018-08-23 Impact factor: 29.690
Authors: Tiina Heliö; Perry Elliott; Juha W Koskenvuo; Juan R Gimeno; Luigi Tavazzi; Michal Tendera; Juan Pablo Kaski; Nicolas Mansencal; Zofia Bilińska; Gerry Carr-White; Thibaud Damy; Andrea Frustaci; Ingrid Kindermann; Tomas Ripoll-Vera; Jelena Čelutkienė; Anna Axelsson; Massimiliano Lorenzini; Aly Saad; Aldo P Maggioni; Cécile Laroche; Alida L P Caforio; Philippe Charron Journal: ESC Heart Fail Date: 2020-08-07